PRIMA-1/PRIMA-1MET reactivates wild-type p53 protein activity and induces cell death in multiple cancer cell lines with different contact and structural p53 mutants, including R110L, V157F, R175H, L194F, R213Q/Y234H, G245V, R248Q, R273C, R273H/P309S, R280K, and R282W and in in vivo tumor models [89–91]. This evidence concerns the gene TP53 and cancer.